Plain-English translation of NCT07363395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a Phase 1 trial testing a new medication called , given as under-the-skin injections. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body processes it. The study involves healthy adult volunteers who will receive different doses of the medication or a placebo (dummy injection) to gather this essential safety information.
Neuropathic pain — pain caused by nerve damage or dysfunction — is difficult to treat with current medications, and many patients don't respond well to available options. This trial is testing a completely new approach to see if this medication might one day help people suffering from this type of chronic pain.
You likely qualify if…
You likely don't qualify if…
You will receive two under-the-skin injections given within 10 minutes of each other, either of the new medication or a placebo. Depending on which part of the study you join, you'll either receive a single dose (Part 1) or multiple doses over time (Part 2). The study involves screening visits, injection visits, and follow-up appointments where blood tests and other assessments will be done to monitor your safety and how your body handles the medication.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States